en · de · es
dihexa-notes.peptides6155.com › Wiki › Identity And Regulatory Status — Evidence Review

Identity And Regulatory Status — Evidence Review

By Editorial Desk · published 2025-12-03 · last reviewed 2026-01-12 · Wiki

synaptogenesis comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2026-01-12. Numbers and descriptions here follow the published literature rather than marketing material.

Identity And Regulatory Status

Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.

Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.

Chemical Identity and Research Background

The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.

Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.

Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.

Dihexa at a glance

PropertyValueNotes
Chemical classSynthetic peptide analogModeled on angiotensin IV
Common synonymsPNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amideResearch codes vary by supplier
AppearanceWhite to off-white powderTypical for lyophilized peptides
SolubilitySoluble in organic solvents; limited in waterFormulation dependent
Typical storage−20 °C, desiccated, protected from lightStability depends on purity and container

Proposed Mechanism and Laboratory Handling

Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.

The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.

Related pages on this site

Research Evidence and Regulation

Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.

Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.

Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.

Further detail

== Pathology == Some metabolic myopathies involve the under- or over-utilization of the purine nucleotide cycle. Metabolic myopathies cause a low ATP reservoir in muscle cells (ADP > ATP), resulting in exercise-induced excessive AMP buildup in muscle, and subsequent exercise-induced hyperuricemia (myogenic hyperuricemia) through conversion of excessive AMP into uric acid by way of either AMP → adenosine or AMP → IMP. During strenuous exercise, AMP is created through the use of the adenylate kinase (myokinase) reaction after the phosphagen system has been depleted of creatine phosphate and not enough ATP is being produced yet by other pathways (see above reaction in 'Occurrence' section). In those affected by metabolic myopathies, exercise that normally wouldn't be considered strenuous for healthy people, is however strenuous for them due to their low ATP reservoir in muscle cells. This results in regular use of the myokinase reaction for normal, everyday activities. Besides the myokinase reaction, a high ATP consumption and low ATP reservoir also increases protein catabolism and salvage of IMP, which results in increased AMP and IMP. These two nucleotides can then enter the purine nucleotide cycle to produce fumarate which will then produce ATP by oxidative phosphorylation. If the purine nucleotide cycle is blocked (such as AMP deaminase deficiency) or if exercise is stopped and increased fumarate production is no longer needed, then the excess nucleotides will be converted into uric acid.

Aden Colony (Arabic: مُسْتْعَمَرَةْ عَدَنْ, romanised: Musta'marat 'Adan) was a crown colony of the United Kingdom from 1937 to 1963 located in the southern part of modern-day Yemen. It consisted of the port city of Aden and also included the outlying islands of Kamaran, Perim and the Khuria Muria archipelago with a total area of 192 km2 (74 sq mi). Initially a key port for the British East India Company, it was annexed by the British in 1839 to secure maritime routes and prevent piracy in the Arabian Sea. Its strategic position at the entrance to the Red Sea made it a vital stopover for ships traveling between Europe, India, and the Far East, especially after the opening of the Suez Canal in 1869. Aden quickly became a major coaling station and transit hub for British shipping, and its significance to the British Empire grew throughout the 19th and early 20th centuries. Prior to 1937, Aden had been governed as part of British India (originally as the Aden Settlement subordinate to the Bombay Presidency, and then as a Chief Commissioner's province). On 1 April 1937, Aden was separated from British India to become a Crown colony under the Government of India Act 1935, consisting of the city of Aden and its surrounding areas. The colony experienced rapid development due to its thriving port, but it was also marked by growing civil unrest. Economic inequality, labour strikes, and the rise of Arab nationalism contributed to increasing tensions, which were intensified by the anti-colonial sentiment in the Middle East.

=== Thioredoxin reductase === Thioredoxin reductase is also a key component of antioxidant defense. Although enzymes carrying out this function is found in most forms of life, the high-molecular-weight selenoprotein version found in animals evolved separately from the more common low-molecular-weight version. This version appears as a branch within the glutathione reductases, again a key component of antioxidant defense.

== C == C3 plant – C4 plant – calcitonin – calmodulin – calorie – Calvin cycle – cancer – capillary – capsid – carbohydrate – carbon fixation – carboxyl group – cardiac muscle – cardiac output – cardiovascular system – carotenoid – cartilage – catabolism – catabolite activator protein – catalyst – catecholamine – celiac disease – cell – cell cycle – cell-mediated immunity – cell membrane – cellular respiration – cellulose – central nervous system – centriole – centrosome – cerebellum – cerebral cortex – cerebrum – chaperonin – chemiosmosis – chemoautotroph – chemoheterotroph – chemoreceptor – chirality – chi-square test – chitin – chlaeniitae – chlamydospore – chlorophyll – chloroplast – cholera – cholesterol – chromatin – chromophore – chromosome – chytrid – circadian rhythm – cloning vector – closed circulatory system – cobalamin – codominance – codon – coenzyme – cofactor – collagen – collecting duct – commensalism – competitive exclusion principle – competitive inhibitor – complementary DNA – complement system – condensation reaction – conidium – cork cambium – corpulentapus – corpus luteum cortex – cotransport – cotyledon – covalent bond – crossing over – cuticle – cyanobacteria – cyclic AMP – cyclin – cyclin-dependent kinase – cytochrome – cytochrome c oxidase – cytochrome P450 – cytokine – cytoplasm – cytotoxic T cell

Gulf War veterans found evidence of a causal link between GWS and exposure to low levels of the nerve agent sarin, which was released into the air by coalition bombing of Iraqi chemical weapons facilities. Significantly, the study found an increased incidence of GWS not only among veterans who recounted hearing nerve agent alarms, but also among veterans with the RR or QR (as opposed to the QQ) forms of the PON1 gene, which produces an enzyme that deactivates organophosphates (including sarin) through hydrolysis. By contrast, GWS was inversely associated with higher levels of the type Q isozyme, which is more efficient at breaking down sarin than its type R counterpart. The authors "found that the PON1 genotype and hearing nerve agent alarms were independent and the findings robust to both measured and unmeasured confounding, supporting a mechanistic [gene–environment] interaction. ... Moreover, the change in the combined effect from one category to the next was significantly greater than the sum of the independent effects of the environmental exposure and the genotype".

Sources: en.wikipedia.org

Supporting material

Adding 60 seconds to this invasive procedure, Kahneman found participants reported the colonoscopy as more pleasant. This was attributed to making sure the colonoscopy instrument was not moved during the extra 60 seconds – movement is the source of the most discomfort. Thus, Kahneman was appealing to the remembering self's tendency to focus on the end of the experience. Such findings help explain human error in affective forecasting – people's ability to predict their future emotional states.

The peer-reviewed journal facilitated discourse around regenerative medicine by publishing innovative research on stem cell therapies, gene therapies, tissue engineering, and biomechanical prosthetics. The Society for Regenerative Medicine, later renamed the Regenerative Medicine and Stem Cell Biology Society, served a similar purpose, creating a community of like-minded experts from around the world. In June 2008, at the Hospital Clínic de Barcelona, Professor Paolo Macchiarini and his team, of the University of Barcelona, performed the first tissue engineered trachea (wind pipe) transplantation. Adult stem cells were extracted from the patient's bone marrow, grown into a large population, and matured into cartilage cells, or chondrocytes, using an adaptive method originally devised for treating osteoarthritis. The team then seeded the newly grown chondrocytes, as well as epithelial cells, into a decellularised (free of donor cells) tracheal segment that was donated from a 51-year-old transplant donor who had died of cerebral hemorrhage. After four days of seeding, the graft was used to replace the patient's left main bronchus. After one month, a biopsy elicited local bleeding, indicating that the blood vessels had already grown back successfully. In 2009, the SENS Foundation was launched, with its stated aim as "the application of regenerative medicine – defined to include the repair of living cells and extracellular material in situ – to the diseases and disabilities of ageing".

Beclabuvir, currently in clinical trials. Dasabuvir (Viekira Pak), non-nucleoside/nucleotide analog, approved by FDA in December 2014 (only in combination with ombitasvir, paritaprevir, and ritonavir). Deleobuvir, development terminated. Filibuvir, development terminated. Radalbuvir, currently in clinical trials. Setrobuvir, development terminated. Sofosbuvir (Sovaldi; Harvoni (combination with ledipasvir)): nucleotide analog, approved by the FDA in December 2013.

Oparin was born in Uglich in 1894 into a merchant family. He and his parents soon moved to Kokayevo, a nearby village. Oparin had an older brother, Dmitry, who became an economist. Oparin graduated from the Moscow State University in 1917 and became a professor of biochemistry there in 1927. Many of his early papers were about plant enzymes and their role in metabolism. His first experimental studies were devoted to the chemistry of respiration. In them, he showed that chlorogenic acid is an essential component of redox reactions in the cell. In 1924 he put forward a hypothesis suggesting that life on Earth developed through a gradual chemical evolution of carbon-based molecules in the Earth's primordial soup. In 1935, along with academician Aleksei Bach, he founded the Biochemistry Institute of the Soviet Academy of Sciences. In 1939, Oparin became a Corresponding Member of the Academy, and, in 1946, a full member. In 1937, he organized the Department of Technical Biochemistry at the Moscow Technological Institute of Food Industry. In 1940s and 1950s, Oparin supported the theories of Trofim Lysenko and Olga Lepeshinskaya, who made claims about "the origin of cells from noncellular matter". "Taking the party line" helped advance his career. However, according to cytologist Vladimir Alexandrov:

=== Coordination compounds === In an acidic aqueous solution, thorium occurs as the tetrapositive aqua ion [Th(H2O)9]4+, which has tricapped trigonal prismatic molecular geometry: at pH < 3, the solutions of thorium salts are dominated by this cation. The Th4+ ion is the largest of the tetrapositive actinide ions, and depending on the coordination number can have a radius between 0.95 and 1.14 Å. It is quite acidic due to its high charge, slightly stronger than sulfurous acid: thus it tends to undergo hydrolysis and polymerisation (though to a lesser extent than Fe3+), predominantly to [Th2(OH)2]6+ in solutions with pH 3 or below, but in more alkaline solution polymerisation continues until the gelatinous hydroxide Th(OH)4 forms and precipitates out (though equilibrium may take weeks to be reached, because the polymerisation usually slows down before the precipitation). As a hard Lewis acid, Th4+ favours hard ligands with oxygen atoms as donors: complexes with sulfur atoms as donors are less stable and are more prone to hydrolysis. High coordination numbers are the rule for thorium due to its large size. Thorium nitrate pentahydrate was the first known example of coordination number 11, the oxalate tetrahydrate has coordination number 10, and the borohydride (first prepared in the Manhattan Project) has coordination number 14. These thorium salts are known for their high solubility in water and polar organic solvents.

Sources: en.wikipedia.org

Notes from published material

30 July – The Parliamentary Commissioner for Standards launches an investigation into Nigel Farage over a potential breach of parliamentary rules over financial interests. Former Downing Street Chief of Staff Sue Gray is appointed to the board of governors of Queen's University Belfast. Adam Holloway, the former Conservative MP for Gravesham, defects to Reform UK. 31 July – James Orr, chairman of the pro-Reform UK think tank, the Centre for a Better Britain, tells the Today programme an incoming Reform government would have to do some "very unpopular" things in its first 100 days in office and force "nasty cough medicine down the country's throat" but that if "Reform ends up governing the country, we should all want them to succeed".

This was adopted by the 7th General Conference on Weights and Measures in 1927. In 1960, the definitions of both the metre and ångström were changed to use krypton. After the industrial scale production of cadmium started in the 1930s and 1940s, the major application of cadmium was the coating of iron and steel to prevent corrosion; in 1944, 62% and in 1956, 59% of the cadmium in the United States was used for plating. In 1956, 24% of the cadmium in the United States was used for a second application in red, orange and yellow pigments from sulfides and selenides of cadmium. The stabilizing effect of cadmium chemicals like the carboxylates cadmium laurate and cadmium stearate on PVC led to an increased use of those compounds in the 1970s and 1980s. The demand for cadmium in pigments, coatings, stabilizers, and alloys declined as a result of environmental and health regulations in the 1980s and 1990s; in 2006, only 7% of total cadmium consumption was used for plating, and only 10% was used for pigments. At the same time, these decreases in consumption were compensated by a growing demand for cadmium for nickel–cadmium batteries, which accounted for 81% of the cadmium consumption in the United States in 2006.

== Toxicity == Studies carried out on the toxicity of convulxin show that symptoms are a function of the dose. The effects of the toxin stand out through the sudden and brief duration of the symptoms after exposure. In mice, low doses (5 μg/animal) administered intravenously (I.V) elicited tachypnea, followed by apnea, within 20 seconds. The ED50 for brief duration apnea was determined to be 180 μg/kg. Higher doses (10 μg/animal) evoked intense convulsive crisis, and usually ended with the death of the animal. LD50 was determined to be 524 μg/kg. Intraperitoneal (I.P.) administration of up to 200 μg/animal proved to be ineffective. In cats, I.V. injections of 100 μg/kg showed respiratory disturbances, miosis, salivation, abdominal cramps, nystagmus, loss of equilibrium, convulsions and sometimes a brief phase of hypotonia. The ED50 dose for convulsions is 80 μg/kg. The majority of animals recovered within 30 minutes. In dogs, the effect of convulxin showed two stages. After I.V. injection of 100-125 μg/kg they became excited, barked and exhibited loss of equilibrium, respiratory disturbances, nystagmus, urination, defecation and vomiting. After recovery, two out of five animals had intermittent crisis of clonic convulsions that appeared after 24 hours and lasted until their death. The other three dogs showed periods of vivid agitation alternating with torpor. While the lethal dose in humans is not yet known, what has been discovered is that the level of toxic effects depends on the origin of the snake. As for a cure, so far a polyvalent snake antivenom is being used.

=== Spectrum of susceptibility === Doxycycline has been used successfully to treat sexually transmitted, respiratory, and eye infections. Representative pathogenic genera include Chlamydia, Streptococcus, Ureaplasma, Mycoplasma, and others. The minimum inhibitory concentration for a few medically significant microorganisms are:

Sources: en.wikipedia.org

Frequently asked questions

What is dihexa?

It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.

Is dihexa a supplement?

It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.

Does dihexa occur naturally?

Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.

What is dihexa?

Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.

Network